CA2928510A1 - Materials and methods for diagnosis and prognosis of liver cancer - Google Patents

Materials and methods for diagnosis and prognosis of liver cancer Download PDF

Info

Publication number
CA2928510A1
CA2928510A1 CA2928510A CA2928510A CA2928510A1 CA 2928510 A1 CA2928510 A1 CA 2928510A1 CA 2928510 A CA2928510 A CA 2928510A CA 2928510 A CA2928510 A CA 2928510A CA 2928510 A1 CA2928510 A1 CA 2928510A1
Authority
CA
Canada
Prior art keywords
name
synonyms
protein
liver
marker proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2928510A
Other languages
English (en)
French (fr)
Inventor
Malcolm Andrew Ward
Ian Hugo Pike
David James BRITTON
Vikram MITRA
Nigel David HEATON
Yoh ZEN
Alberto Quaglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Kings College Hospital NHS Foundation Trust
Original Assignee
Electrophoretics Ltd
Kings College Hospital NHS Foundation Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd, Kings College Hospital NHS Foundation Trust filed Critical Electrophoretics Ltd
Publication of CA2928510A1 publication Critical patent/CA2928510A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Gastroenterology & Hepatology (AREA)
CA2928510A 2013-11-13 2014-11-13 Materials and methods for diagnosis and prognosis of liver cancer Abandoned CA2928510A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1320061.3 2013-11-13
GBGB1320061.3A GB201320061D0 (en) 2013-11-13 2013-11-13 Materials nad methods for diagnosis and prognosis of liver cancer
PCT/GB2014/053368 WO2015071669A2 (en) 2013-11-13 2014-11-13 Materials and methods for diagnosis and prognosis of liver cancer

Publications (1)

Publication Number Publication Date
CA2928510A1 true CA2928510A1 (en) 2015-05-21

Family

ID=49818578

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2928510A Abandoned CA2928510A1 (en) 2013-11-13 2014-11-13 Materials and methods for diagnosis and prognosis of liver cancer

Country Status (6)

Country Link
US (1) US20160320395A1 (https=)
EP (1) EP3069142A2 (https=)
JP (1) JP2016538545A (https=)
CA (1) CA2928510A1 (https=)
GB (1) GB201320061D0 (https=)
WO (1) WO2015071669A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105288659B (zh) * 2015-06-01 2019-07-26 北京泱深生物信息技术有限公司 Tenm1基因及其表达产物在诊治乳头状腺癌的应用
KR101750411B1 (ko) 2015-07-10 2017-06-27 한국생명공학연구원 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
EP3403100B1 (fr) * 2016-01-15 2020-03-11 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Procédé de diagnostic in vitro d'atteintes hépatiques
FR3048780B1 (fr) * 2016-03-11 2020-11-06 Commissariat Energie Atomique Procede de diagnostic in vitro d'atteintes hepatiques
GB201616912D0 (en) * 2016-10-05 2016-11-16 University Of East Anglia Classification of cancer
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
IL314915B1 (en) 2017-01-23 2026-02-01 Regeneron Pharma Variants of 17-beta-hydroxysteroid dehydrogenase and their uses
CN115266962B (zh) * 2017-03-31 2024-05-31 北京谷海天目生物医学科技有限公司 蛋白标志物在制备弥漫型胃癌分子分型的产品中的应用及弥漫型胃癌分子分型的分类器
KR20190139869A (ko) 2017-04-11 2019-12-18 리제너론 파마슈티칼스 인코포레이티드 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
WO2018189215A1 (en) * 2017-04-12 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from hepatocellular carcinoma
US10961583B2 (en) 2017-10-11 2021-03-30 Regeneron Phramaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
CN109596829A (zh) * 2017-12-07 2019-04-09 南京医科大学 一种肝癌标志蛋白及其检测方法
WO2019115679A1 (en) * 2017-12-13 2019-06-20 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol A signature to assess prognosis and therapeutic regimen in liver cancer
JP7507093B2 (ja) 2018-03-21 2024-06-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド １７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法
US20220244263A1 (en) * 2019-05-28 2022-08-04 The Regents Of The University Of California Methods for treating small cell neuroendocrine and related cancers
BR112022015303A2 (pt) * 2020-02-10 2022-09-27 Somalogic Operating Co Inc Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos
WO2021175863A1 (en) * 2020-03-02 2021-09-10 Université De Strasbourg Method for diagnosis and/or prognosis of liver disease progression and risk of hepatocellular carcinoma and discovery of therapeutic compounds and targets to treat liver disease and cancer
JP7471898B2 (ja) * 2020-04-17 2024-04-22 合同会社Ｈ．Ｕ．グループ中央研究所 胆管がんのバイオマーカー
CN111748624B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 用于预测肝癌是否复发的生物标志物
CN111748623B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 肝癌患者是否复发的预测标志物及试剂盒
CN112961916B (zh) * 2020-11-10 2024-03-12 上海市肿瘤研究所 Akr1c3作为肝癌预后的生物学标志物及其应用
CN112908470B (zh) * 2021-02-08 2023-10-03 深圳市人民医院 一种基于rna结合蛋白基因的肝细胞癌预后评分系统及其应用
CN113462777A (zh) * 2021-06-28 2021-10-01 武汉大学 P4hb在制备肝细胞癌早期诊断试剂盒及制备或筛选抗肝癌药物中的应用
CN114814001B (zh) * 2022-03-31 2023-02-21 武汉大学 用于制备肝癌检测试剂的新型代谢标志物及其应用
CN115754290A (zh) * 2022-09-26 2023-03-07 浙江大学 一种用于检测早期肝癌的试剂盒
CN115807089B (zh) * 2022-11-14 2024-09-13 石河子大学 肝细胞肝癌预后生物标志物及应用
CN116338189B (zh) * 2023-01-16 2025-08-22 浙江大学医学院附属第一医院 具有蛋白激酶功能的肿瘤标志物ckb在制备肿瘤诊断产品中的应用
CN116386715A (zh) * 2023-03-09 2023-07-04 福建医科大学孟超肝胆医院 用于原发性肝细胞癌蛋白质组分子分型诊断的特征蛋白及其应用
CN117607438A (zh) * 2023-11-23 2024-02-27 浙江大学 一种肝细胞癌鉴别诊断和分化程度检测方法
CN119314683B (zh) * 2024-12-17 2025-02-25 吉林大学第一医院 一种用于肝移植术后预测系统

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE508361T1 (de) 2001-08-14 2011-05-15 Harvard College Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie
EP1831697A4 (en) * 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SEARCH FOR TUBULINISOTYPES IN CANCER THERAPY USING HALICHONDRIN B ANALOG
US20060148014A1 (en) * 2004-12-09 2006-07-06 Sergei Agoulnik Tubulin isotype screening in cancer therapy using hemiasterlin analogs
US20080161203A1 (en) * 2006-12-27 2008-07-03 Su Chun-Lin Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
JPWO2009113495A1 (ja) * 2008-03-12 2011-07-21 財団法人ヒューマンサイエンス振興財団 肝癌特異的発現遺伝子による肝癌の検査方法並びに肝癌の治療及び予防剤
WO2011078311A1 (ja) * 2009-12-25 2011-06-30 大鵬薬品工業株式会社 肝細胞癌治療のための抗腫瘍剤又は術後補助化学療法剤
JP2014525584A (ja) * 2011-08-31 2014-09-29 オンコサイト コーポレーション 癌の治療および診断のための方法および組成物

Also Published As

Publication number Publication date
GB201320061D0 (en) 2013-12-25
EP3069142A2 (en) 2016-09-21
US20160320395A1 (en) 2016-11-03
WO2015071669A3 (en) 2015-09-17
JP2016538545A (ja) 2016-12-08
WO2015071669A2 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
CA2928510A1 (en) Materials and methods for diagnosis and prognosis of liver cancer
US20220397576A1 (en) Apparatuses and methods for detection of pancreatic cancer
Sun et al. Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma
AU2014364520B2 (en) Methods and assays relating to circulating tumor cells
US11662352B2 (en) Erythrocyte-derived extracellular vesicles and proteins associated with such vesicles as biomarkers for parkinson's disease
US20120039811A1 (en) Markers for cancer detection
CA2875418A1 (en) Method and agents to quantify proteins from tissues
JP2025522362A (ja) マルチオミクス評価
EP3071972B1 (en) Method for in vitro diagnosing and prognosing of triple negative breast cancer recurrence
ES2953011T3 (es) Agrina como marcador de cáncer de endometrio
US20210095348A1 (en) Methods and systems to perform genetically variant protein analysis, and related marker genetic protein variations and databases
US10480034B2 (en) Cancer biomarker and diagnostic
Pastor et al. Proteomic biomarkers in lung cancer
Valdés et al. Proteomic comparison between different tissue preservation methods for identification of promising biomarkers of urothelial bladder cancer
Baldan-Martin et al. Tissue proteomic approaches to understand the pathogenesis of inflammatory bowel disease
Arai et al. Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis
Meleady et al. Proteomic analysis of pancreatic ductal adenocarcinoma
Alexovič et al. In Search of Candidate Protein Biomarkers Related to COVID‐19 in Solid Tissues and Non‐Blood Fluids: An Update
Zamò et al. Proteomic analysis of lymphoid and haematopoietic neoplasms: there's more than biomarker discovery
US20150104809A1 (en) Detection and treatment of cancer
Kobayashi et al. Proteomic profiling of FFPE specimens: Discovery of HNRNPA2/B1 and STT3B as biomarkers for determining formalin fixation durations
Gao et al. Identification and verification of the main differentially expressed proteins in gastric cancer via iTRAQ combined with liquid chromatography‐mass spectrometry
WO2022246565A1 (en) Methods and kits for diagnosing systemic autoimmune rheumatic diseases
Ni et al. The general law of plasma proteome alterations occurring in the lifetime of Chinese individuals reveals the importance of immunity
AU2014233935A1 (en) Brucellosis, Q-Fever, and Lyme Disease biomarkers and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210204